COMMUNIQUÉS West-GlobeNewswire

Galapagos receives transparency notification from FMR LLC

03/09/2024 - 22:01

Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation 1 , [...]

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

03/09/2024 - 22:01

WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will [...]

Nkarta to Participate in Upcoming Investor Conference

03/09/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the [...]

HealthEquity Reports Second Quarter Ended July 31, 2024 Financial Results

03/09/2024 - 22:01

Announces $300 Million Stock Repurchase Program Highlights of the second quarter include: Revenue of $299.9 million, an increase of 23% compared to $243.5 million in Q2 FY24. Net income of $35.8 million, compared to $10 [...]

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

03/09/2024 - 22:01

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s disease or who are [...]

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

03/09/2024 - 22:00

NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers [...]

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

03/09/2024 - 22:00

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in [...]

USAHS Sponsors Seventh Annual U.S. Open Adaptive Surfing Championship

03/09/2024 - 20:07

The University’s students will play a major part in assisting athletes and ensuring their safety at the event OCEANSIDE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- For the seventh year, the University of St. Augustine [...]

7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

03/09/2024 - 20:02

HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- 7 Hills Pharma Inc. (“7 Hills” or “7HP”), a clinical-stage pharma company advancing first-in-class integrin activators designed to safely enhance cancer immunotherapies, [...]

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

03/09/2024 - 18:30

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 18:15

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H [...]

Informations relatives au nombre total de droits de vote et d’actions composant le capital

03/09/2024 - 18:00

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 septembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device

02/09/2024 - 22:05

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end [...]

Nyxoah Sonne la Cloche de Clôture sur le Nasdaq alors qu'elle se Prépare à Lancer sa Technologie Innovante pour l'Apnée du Sommeil sur le Marché Américain

02/09/2024 - 22:05

Nyxoah Sonne la Cloche de Clôture sur le Nasdaq alors qu'elle se Prépare à Lancer sa Technologie Innovante pour l'Apnée du Sommeil sur le Marché Américain L'entreprise a complété la demande d'enregistrement [...]

Trading by management and close relations of management

02/09/2024 - 18:36

Please read the full announcement in PDF Attachment 2024_31_Trading_By_Management

Trading by management and close relations of management

02/09/2024 - 18:27

Please read the full announcement in PDF Attachment 2024_30_Trading_By_Management

Amended terms of Idorsia’s 2024 convertible bonds become effective

02/09/2024 - 17:45

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the [...]

Claritas NucMed Technologies Secures Approval for its Subsidiary Claritas NucMed Tech Brazil to Forge Ahead the Commercialization of its Cutting-Edge Nuclear Medicine Software Solutions in Brazil

02/09/2024 - 16:00

LONDON and SAO PAULO, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (“Claritas NucMed”), a company specializing in image processing, lesion detection and quantification for the nuclear medicine [...]

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

02/09/2024 - 13:45

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action —Largest randomized data set to date on bioadaptor, with [...]